Lumpy skin disease(LSD)is a highly contagious disease caused by lumpy skin disease virus(LSDV)in bovines.Rapid and accurate diagnosis is very important to controll it.However,current commercial detection kits need to ...Lumpy skin disease(LSD)is a highly contagious disease caused by lumpy skin disease virus(LSDV)in bovines.Rapid and accurate diagnosis is very important to controll it.However,current commercial detection kits need to be improved in terms of sensitivity or specificity.This study aimed to develop a novel diagnostic competitive enzyme-linked immunosorbent assay(cELISA)based on the newly identified antigen gene LSDV034.The rLSDV034 protein was identified as a potential diagnostic antigen,and it was expressed,purified,and used to immunize BALB/c mice.Using laboratory-prepared indirect ELISA(iELISA),the positive cell lines were screened,and their blocking activity was further verified by competitive ELISA(cELISA).The cell line,1H7,was chosen to produce mouse ascites,which were purified for a monoclonal antibody(mAb,5.395 mg/mL).The heavy chain type of the 1H7 mAb was identified as IgG1a,and its light chain subtype was identified as κ.Furthermore,cELISA was developed to detect bovine serum antibodies,with rLSDV034(4μg/mL)as the coating antigen and HRP-1H7 mAb(1:300)as the competitive antibody.The cutoff value of cELISA was 55%,based on 32 negative bovine serum samples.The analytical sensitivity was 1:8,and no cross-reaction was detected with bovine viral diarrhea virus(BVDV),infectious bovine rhinotracheitis virus(IBRV),Pasteurella multocida(P.multocida),or Mycoplasma bovis(M.bovis)from the serum samples.The diagnostic sensitivity and specificity of cELISA were 98.46%(95%confidence interval,CI:91.7–100)and 100%(95%CI:89.1–100),respectively,based on the analysis of 30 LSDV-infected bovine serum samples,35 GTPV-vaccinated samples,and 32 negative samples.The overall coincidence of the cELISA with the virus neutralization test(VNT)reached 98.97%(95%CI:94.4–100).Furthermore,we used cELISA to analyze 230 clinical bovine serum samples(including 59 infected and 171 vaccinated samples)and found that the serum positivity rates of the immunized samples(on d 60 postimmunization)and infected samples were 77.78%(95%CI:70.8–83.8%)and 71.19%(95%CI:57.9–82.2),respectively.These results indicate that the developed cELISA is promising for detecting serum antibodies in naturally infected or vaccinated cattle.展开更多
Solution-processed quantum dot light-emitting diodes(QLEDs)hold great potential as competitive candidates for display and lighting applications.However,the serious energy disorder between the quantum dots(QDs)and hole...Solution-processed quantum dot light-emitting diodes(QLEDs)hold great potential as competitive candidates for display and lighting applications.However,the serious energy disorder between the quantum dots(QDs)and hole transport layer(HTL)makes it challenging to achieve high-performance devices at lower voltage ranges.Here,we introduce"giant"fully alloy CdZnSe/ZnSeS core/shell QDs(size~19 nm)as the emitting layer to build high-efficient and stable QLEDs.The synthesized CdZnSe-based QDs reveal a decreased ground-state band splitting,shallow valence band maximum,and improved quasi-Fermi level splitting,which effectively flatten the energy landscape between the QD layer and hole transport layer.The higher electron concentration and accelerated hole injection significantly promote the carrier radiative recombination dynamics.Consequently,CdZnSe-based device exhibits a high power conversion efficiency(PCE)of 27.3%and an ultra-low efficiency roll-off,with a high external quantum efficiency(EQE)exceeding 25%over a wide range of low driving voltages(1.8-3.0V)and low heat generation.The record-high luminance levels of 1,400 and 8,600 cd m^(-2)are achieved at bandgap voltages of 100%and 120%,respectively.Meanwhile,These LEDs show an unprecedented operation lifetime T_(95)(time for the luminance to decrease to 95%)of 72,968 h at 1,000 cd m^(-2).Our work points to a novel path to flatten energy landscape at the QD-related interface for solution-processedphotoelectronicdevices.展开更多
Background and aim:Data on the radiologic evaluation of perianal fistulizing Crohn’s disease(PFCD)naive to anti-tumor necrosis factor therapy are scarce,especially in Asian populations.We assessed the effectiveness o...Background and aim:Data on the radiologic evaluation of perianal fistulizing Crohn’s disease(PFCD)naive to anti-tumor necrosis factor therapy are scarce,especially in Asian populations.We assessed the effectiveness of infliximab(IFX)on PFCD and explored predictors of‘deep remission’based on clinical and radiologic assessments.Methods:Patients with Crohn’s disease and active anal fistulas attending our care center for IFX therapy were prospectively enrolled.Each patient underwent clinical examination according to the Fistula Drainage Assessment Index,endoscopy for assessment of Crohn’s Disease Activity Index(CDAI)and Perianal Crohn’s Disease Activity Index(PCDAI),magnetic resonance imaging(MRI)to determine Van Assche score and Ng score,and laboratory tests up to 2 weeks prior to the start of and up to 2 weeks after the sixth IFX therapy(Week 32).Results:Among 38 patients treated with IFX,52.6%achieved clinical remission based on the Fistula Drainage Assessment Index and 42.1%achieved deep remission based on Ng score.Van Assche score(from 14.5±4.26 to 7.36±7.53),CDAI(from 170±92 to 71±69)and PCDAI(from 7.45±2.65 to 2.44±3.20)decreased significantly after six IFX treatments.The only predictor of deep remission was simple fistula(P=0.004,odds ratio=3.802,95%confidence interval:1.541–9.383).Conclusions:IFX has been shown to have appreciable effectiveness in Chinese patients with PFCD.MRI is the gold standard for evaluating PFCD,but Van Assche score has some limitations.展开更多
基金financially supported by the National Key Research and Development Program of China(#2022YFD1800701)the Key Research and Development Program of the Ningxia Hui Autonomous Region(#2021BEF02028)the Chinese Agricultural Research System of MOF and MARA(#CARS-37).
文摘Lumpy skin disease(LSD)is a highly contagious disease caused by lumpy skin disease virus(LSDV)in bovines.Rapid and accurate diagnosis is very important to controll it.However,current commercial detection kits need to be improved in terms of sensitivity or specificity.This study aimed to develop a novel diagnostic competitive enzyme-linked immunosorbent assay(cELISA)based on the newly identified antigen gene LSDV034.The rLSDV034 protein was identified as a potential diagnostic antigen,and it was expressed,purified,and used to immunize BALB/c mice.Using laboratory-prepared indirect ELISA(iELISA),the positive cell lines were screened,and their blocking activity was further verified by competitive ELISA(cELISA).The cell line,1H7,was chosen to produce mouse ascites,which were purified for a monoclonal antibody(mAb,5.395 mg/mL).The heavy chain type of the 1H7 mAb was identified as IgG1a,and its light chain subtype was identified as κ.Furthermore,cELISA was developed to detect bovine serum antibodies,with rLSDV034(4μg/mL)as the coating antigen and HRP-1H7 mAb(1:300)as the competitive antibody.The cutoff value of cELISA was 55%,based on 32 negative bovine serum samples.The analytical sensitivity was 1:8,and no cross-reaction was detected with bovine viral diarrhea virus(BVDV),infectious bovine rhinotracheitis virus(IBRV),Pasteurella multocida(P.multocida),or Mycoplasma bovis(M.bovis)from the serum samples.The diagnostic sensitivity and specificity of cELISA were 98.46%(95%confidence interval,CI:91.7–100)and 100%(95%CI:89.1–100),respectively,based on the analysis of 30 LSDV-infected bovine serum samples,35 GTPV-vaccinated samples,and 32 negative samples.The overall coincidence of the cELISA with the virus neutralization test(VNT)reached 98.97%(95%CI:94.4–100).Furthermore,we used cELISA to analyze 230 clinical bovine serum samples(including 59 infected and 171 vaccinated samples)and found that the serum positivity rates of the immunized samples(on d 60 postimmunization)and infected samples were 77.78%(95%CI:70.8–83.8%)and 71.19%(95%CI:57.9–82.2),respectively.These results indicate that the developed cELISA is promising for detecting serum antibodies in naturally infected or vaccinated cattle.
基金funded by the National Natural Science Foundation of China(Grant Nos.22205054,U22A2072,61922028,22175056,and 22479041)Zhongyuan High-Level Talents Special Support Plan(No.244200510009)+1 种基金the National Key R&D Program of China(Grant No.2023YFE0205000)Postdoctoral Research Grant in Henan Province(No.202103041).
文摘Solution-processed quantum dot light-emitting diodes(QLEDs)hold great potential as competitive candidates for display and lighting applications.However,the serious energy disorder between the quantum dots(QDs)and hole transport layer(HTL)makes it challenging to achieve high-performance devices at lower voltage ranges.Here,we introduce"giant"fully alloy CdZnSe/ZnSeS core/shell QDs(size~19 nm)as the emitting layer to build high-efficient and stable QLEDs.The synthesized CdZnSe-based QDs reveal a decreased ground-state band splitting,shallow valence band maximum,and improved quasi-Fermi level splitting,which effectively flatten the energy landscape between the QD layer and hole transport layer.The higher electron concentration and accelerated hole injection significantly promote the carrier radiative recombination dynamics.Consequently,CdZnSe-based device exhibits a high power conversion efficiency(PCE)of 27.3%and an ultra-low efficiency roll-off,with a high external quantum efficiency(EQE)exceeding 25%over a wide range of low driving voltages(1.8-3.0V)and low heat generation.The record-high luminance levels of 1,400 and 8,600 cd m^(-2)are achieved at bandgap voltages of 100%and 120%,respectively.Meanwhile,These LEDs show an unprecedented operation lifetime T_(95)(time for the luminance to decrease to 95%)of 72,968 h at 1,000 cd m^(-2).Our work points to a novel path to flatten energy landscape at the QD-related interface for solution-processedphotoelectronicdevices.
基金This work was supported by the National Natural Science Foundation of China(No.81302092,81302095 and 81600435)the Fundamental Research Funds for the Central Universities(No.YG2015QN38)the Foundation for Fostering Clinical Research of Renji Hospital(No.PYMDT-005).
文摘Background and aim:Data on the radiologic evaluation of perianal fistulizing Crohn’s disease(PFCD)naive to anti-tumor necrosis factor therapy are scarce,especially in Asian populations.We assessed the effectiveness of infliximab(IFX)on PFCD and explored predictors of‘deep remission’based on clinical and radiologic assessments.Methods:Patients with Crohn’s disease and active anal fistulas attending our care center for IFX therapy were prospectively enrolled.Each patient underwent clinical examination according to the Fistula Drainage Assessment Index,endoscopy for assessment of Crohn’s Disease Activity Index(CDAI)and Perianal Crohn’s Disease Activity Index(PCDAI),magnetic resonance imaging(MRI)to determine Van Assche score and Ng score,and laboratory tests up to 2 weeks prior to the start of and up to 2 weeks after the sixth IFX therapy(Week 32).Results:Among 38 patients treated with IFX,52.6%achieved clinical remission based on the Fistula Drainage Assessment Index and 42.1%achieved deep remission based on Ng score.Van Assche score(from 14.5±4.26 to 7.36±7.53),CDAI(from 170±92 to 71±69)and PCDAI(from 7.45±2.65 to 2.44±3.20)decreased significantly after six IFX treatments.The only predictor of deep remission was simple fistula(P=0.004,odds ratio=3.802,95%confidence interval:1.541–9.383).Conclusions:IFX has been shown to have appreciable effectiveness in Chinese patients with PFCD.MRI is the gold standard for evaluating PFCD,but Van Assche score has some limitations.
